Toxic epidermal necrolysis: Retrospective analysis of 21 consecutive cases managed at a tertiary centre

Clinical and Experimental Dermatology

Volumn 35, Issue 8, 2010, Pages 853-862

  Rajaratnam, R ^a   Mann, C ^a   Balasubramaniam, P ^a   Marsden, J R ^a   Taibjee, S M ^a   Shah, F ^a   Lim, R ^a   Papini, R ^a   Moiemen, N ^a   Lewis, H ^a  

^a SELLY OAK HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; IMMUNOGLOBULIN G;

ACINETOBACTER; ADULT; AGED; ANEMIA; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; COHORT ANALYSIS; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG EFFECT; ENTEROCOCCUS; FEMALE; FLUID BALANCE; HUMAN; KIDNEY FAILURE; LYMPHOCYTOPENIA; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MORTALITY; NEUTROPENIA; NEUTROPHILIA; NOSE FEEDING; PARENTERAL NUTRITION; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; SEPSIS; STAPHYLOCOCCUS AUREUS; SYMBLEPHARON; TERTIARY HEALTH CARE; TOXIC EPIDERMAL NECROLYSIS; VISUAL IMPAIRMENT; WOUND CARE;

ADOLESCENT; ADRENAL CORTEX HORMONES; ADULT; AGED; AGED, 80 AND OVER; BURN UNITS; CYCLOPHOSPHAMIDE; CYCLOSPORINE; ENGLAND; EPIDERMAL NECROLYSIS, TOXIC; FEMALE; HOSPITALS, UNIVERSITY; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; YOUNG ADULT;

EID: 78149385785     PISSN: 03076938     EISSN: 13652230     Source Type: Journal    
DOI: 10.1111/j.1365-2230.2010.03826.x     Document Type: Article

References (21)

1. Chave TA, Mortimer NJ, Sladden MJ et al. Toxic epidermal necrolysis: current evidence, practical management and future directions. Br J Dermatol 2005; 153: 241-53.
2. Pereira FA, Mudgil AV, Rosmarin DM. Toxic epidermal necrolysis. J Am Acad Dermatol 2007; 56: 181-99.
3. Halevy S, Ghislain PD, Mockenhaupt M et al. Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel. J Am Acad Dermatol 2008; 58: 25-32.
4. Lyell A. Toxic epidermal necrolysis: an eruption resembling scalding of the skin. Br J Dermatol 1956; 68: 355-61.
5. Bastuji-Garin S, Fouchard N, Bertocchi M et al. SCORTEN. A severity-of-illness score for toxic epidermal necrolysis. J Invest Dermatol 2000; 115: 149-53.
6. Yeung CK, Lam LK, Chan HH. The timing of intravenous immunoglobulin therapy in Stevens-Johnson syndrome and toxic epidermal necrolysis. Clin Exp Dermatol 2005; 30: 578-602.
7. Prins C, Kerdel FA, Padilla RS. Treatment of toxic epidermal necrolysis with high dose intravenous immunoglobulins. Multicenter retrospective analysis of 48 consecutive cases. Arch Dermatol 2003; 139: 26-32.
8. Wong KC, Kennedy PJ, Lee S. Clinical manifestations and outcomes in 17 cases of Stevens-Johnson and toxic epidermal necrolysis. Aust J Dermatol 1999; 40: 131-4.
9. Gravante G, Delogu D, Esposito G et al. Toxic epidermal necrolysis in oncologic patients. Am J Clin Dermatol 2006; 7: 397-8.
10. Trent JT, Kirsner RS, Romanelli P et al. Use of SCORTEN to accurately predict mortality in patients with toxic epidermal necrolysis in the United States. Arch Dermatol 2004; 140: 890-2.
11. Yarbrough DR 3rd. Experience with toxic epidermal necrolysis treated in a burn center. J Burn Care Rehabil 1996; 17: 30-3.
12. Heng MCY, Allen SG. Efficacy of cyclophosphamide in toxic epidermal necrolysis. J Am Acad Dermatol 1991; 25: 778-86.
13. Arevalo JM, Lorente JA, Gonzalez-Herrada C et al. Treatment of toxic epidermal necrolysis with cyclosporin A. J Trauma 2000; 48: 473-8.
14. Viard I, Wehrli P, Bullani R et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 1998; 282: 490-3.
15. Mittmann N, Chan B, Knowles S et al. Intravenous immunoglobulin use in patients with toxic epidermal necrolysis and Stevens-Johnson syndrome. Am J Clin Dermatol 2006; 7: 359-68.
16. Shortt R, Gomez M, Mittman N et al. Intravenous immunoglobulin does not improve outcome in toxic epidermal necrolysis. J Burn Care Rehabil 2004; 25: 246-55.
17. Brown KM, Silver GM, Halerz M et al. Toxic epidermal necrolysis: does immunoglobulin make a difference? J Burn Care Rehabil 2004; 25: 81-8.
18. Kazatchkine MD, Kaveri SV. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med 2001; 345: 745-53.
19. Halebian PH, Madden MR, Finkelstein JL et al. Improved burn center survival of patients with toxic epidermal necrolysis managed without corticosteroids. Ann Surg 1986; 204: 503-12.
20. Schneck J, Fagot JP, Sekula P et al. Effects of treatment on the mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis: a retrospective study on patients included in the prospective EuroSCAR study. J Am Acad Dermatol 2008; 58: 33-40.
21. Blum L, Chosidow O, Rostoker G et al. Renal involvement in toxic epidermal necrolysis. J Am Acad Dermatol 1996; 34: 1088-90.